Yingbin West Road, North District, Hantai Economic Development Zone, Hanzhong city, Shaanxi Province
No.6 Gaoxin Avenue, Chuangzhi Industrial Park, Hanzhong Economic and Technological Development Zone, Shaanxi Province
Scan the code to pay attention to the public number
Warmly celebrate the "Kickoff Meeting of Experts Consensus on Clinical Application of Qiangli Dingxuan Tablets" was successfully held
Release time ：
Kickoff meeting of expert consensus on clinical application of Qiangli Dingxuan tablets
In order to thoroughly implement the spirit of the "Opinions of the Central Committee of the Communist Party of China and the State Council on Promoting the Inheritance, Innovation and Development of Traditional Chinese Medicine", explore the establishment of a clinical value-oriented evaluation path, comprehensively use evidence-based medicine and other methods, and promote the standardization of the clinical application of traditional Chinese medicine, To promote clinical rational drug use, the "Kingqiang Dingxuan Tablet Clinical Application Expert Consensus Launch Meeting" hosted by the Chinese Association of Traditional Chinese Medicine, undertaken by the Cardiovascular Branch of the Chinese Association of Traditional Chinese Medicine, and co-organized by Shaanxi Hanwang Pharmaceutical Co., Ltd. was held in Shaanxi on April 18. Hanzhong was successfully held.
This meeting gathered more than 20 experts from the society, including Professor Li Yingdong, Vice Chairman of the Cardiovascular Branch of the Chinese Medical Association, and Professor Yao Kuiwu, Vice Chairman and Secretary General of the Cardiovascular Branch of the Chinese Medical Association, to discuss the "Strong Daze" Expert Consensus on Clinical Application of Qiangqiang Dingxuan Tablets", and put forward valuable revision opinions, aiming to clarify the clinical positioning of Qiangqi Dingxuan tablets, that is, to reasonably interpret the disease application scope and syndrome application characteristics of Qiangqi Dingxuan tablets, so as to obtain the medication experience of authoritative experts , and finally reached a consensus to improve the standardization of clinical application of Qiangli Dingxuan tablets and promote clinical rational drug use.
At the meeting, Professor Yao Kuiwu put forward suggestions on the drafting and project approval of the strong Dingxuan tablet consensus, clinical application, clinical application suggestions, and consensus work progress and arrangement. Detailed interpretation of the expert consensus formulation process for clinical application of patented drugs. During the discussion session, the experts present came to formulate the consensus plan in turn, and gave professional and feasible suggestions and opinions based on clinical experience and product characteristics. The discussion atmosphere was lively and the academic interaction was strong, and the meeting reached a preliminary consensus.
Qiangli Dingxuan Tablet is a patented product with independent intellectual property rights successfully developed by Shaanxi Hanwang Pharmaceutical Co., Ltd. in 1980, and was approved by the State Food and Drug Administration in August 1981. Qiangli Dingxuan Tablet is mainly composed of Gastrodia elata, Eucommia ulmoides, wild chrysanthemum, Eucommia leaves, and Chuanxiong. For hypertension, arteriosclerosis, hyperlipidemia and headache, dizziness, dizziness, tinnitus, insomnia and other diseases caused by the above diseases.
At present, the "Expert Consensus on Clinical Application of Qiangli Dingxuan Tablets" has been approved by the Chinese Association of Traditional Chinese Medicine and announced. The formulation of consensus is also progressing steadily.
After the meeting, the expert group visited the modern Chinese medicine production base of Hanwang Pharmaceutical.
Feng Zhenbin, chairman and general manager of Hanwang Pharmaceutical, and company leaders and market managers of various districts attended the meeting.